Philips Collaborates With Leading Institutes to Combine Its Spectral CT Imaging and Image-Guided Therapy Technologies for Interventional Suite

November 24, 2021—Royal Philips announced it is collaborating with leading clinical institutes such as Mayo Clinic in Rochester, Minnesota and Baptist Health’s Miami Cardiac & Vascular Institute in Miami, Florida, to bring its spectral CT imaging technology into a hybrid angio CT suite. The company aims to combine its Spectral CT 7500 system and its Azurion with FlexArm image-guided therapy system in a single interventional suite solution. The company is presenting the technology at the RSNA 2021, the Radiological Society of North America’s annual meeting held November 28 to December 2 in Chicago, Illinois.

According to Royal Philips, combining its Spectral CT 7500 with its Azurion platform will provide a seamless workflow environment in which all the necessary imaging modalities are available directly at the patient table, fully controllable from the table-side work spot. Each system can work stand-alone, if required. When not in use, each modality glides away from the patient table into a parking position, giving the interventional team unrestricted access to the patient.

Philips stated that its always-on spectral CT technology requires one scan to capture all the spectral information required to differentiate and quantify different tissues. It enables improved detection, delineation, and quantification of lesions for better-informed planning for minimally invasive procedures and more precise interventions. In oncology, spectral CT has also demonstrated a higher sensitivity in detecting malignant findings and has improved readings of incidental findings, noted the company.

“There has been a tremendous evolution in the image-guided therapy environment,” commented Barry T. Katzen, MD, in Philips’ press release. Dr. Katzen, who is the Founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute, continued, “We are really excited about the merger and integration of these technologies in that it might allow us to look at the treatment of a number of diseases in very new and innovative ways, potentially offering new treatment opportunities and improving patient care. I am looking forward to investigating the possibilities of this promising innovation.”